Reporter On-line Economic Observer Qi Jiaqi Shen Shuhong After the case of Cheng Zhen, general manager of the Shenzhen and Mei Women Women's and Pediatric Hospital, after deciding with the "Gene Editing Baby Event", the central character "Gene Editing Baby Event", He Jiankui, also denied. This event is related.
At this point, the location of the lab in the "Gene Editing Baby Event" remains an unresolved mystery.
In the afternoon of November 27, the reporter went to Bohai Gene, in the Shenyuan building in Luohu, Shenzhen, and the company's technical director, Zhou, explicitly denied Bohai Gene Laboratory as a laboratory in the Gene Editing Baby Project. In response to a reporter on the Economic Observer website, he said he also learned of yesterday's news incident and said "Bohai Gene has not invested in this project in terms of people, money or resources."
He added, "He Jiankui is basically responsible only for the strategic development of Bohai Gene, and does not participate in the direct management of the company.
Previously, it was speculated that Bohai Gene would probably be the site of the experimental study of the genetically edited baby project, because Bohai Gene is more powerful in various enterprises under the name of He Jiankui.
According to Tianyue, the Bohai Gene was established on July 4, 2012. It is a biotechnology company specializing in bioinformatics analysis services. He Jiankui is the legal representative and largest shareholder of Bohai Gene, directly holding 27.41% of Bohai Gene, and subsequently indirectly holds 5.83% of Bohai Gene through the Zhuhai Bohai Chuangmeng Technology Management Partnership. The company's assessment in 2017 amounted to 1.5 billion yuan. The company announced on April 19 this year that it has completed the $ 218 million Series A financing, which is also the fourth round of funding for Bohai Gene.
Regarding the rumors, the official said: "If this project is related to the Bohai gene, it will pass through our hand, but not really." He explained that the main business of Bohai Gene is the production of gene sequencer and genetic editing is two concepts. "Gene sequencing is the process of reading DNA, our goal is to read a DNA sequence of 3 billion characters in the human body to determine the health risks that may exist in a person, and the sample used in the study was artificial Synthetic DNA, non-biological DNA The editing of genes is the modification of DNA, which is two completely different technologies. "
At the same time, he said that from the standpoint of the company's R & D team, Bohai Technology is currently not enough to have the ability to supplement or aid the genetic editing of experimental research on babies. "Bohai Gene has less than 140 employees and about 80 R & D staff. Research and development is mainly sequencing, sequencing reagents and bioinformatics algorithms, including sequencing and sequencing reagents in the field of optical manufacturing and genetic editing technology.The difference is very small: there are less than 5 bioinformatics researchers, that is, the "code" capable of understanding DNA display, and people who can read useful information are rare, and bioinformatics and biomedical are not in the same professional field and can not be assisted.
Currently, the gene sequencer from Bohai Gene Production has not yet been approved by the relevant departments. In this regard, Bohai Gene said that everything has a process, the company has been moving forward, everything is legal and compatible.
In addition, the Shenzhen Science and Technology Commission also circulated in the market to provide financial assistance to the "Gene Editing Baby Project". In response, the official said: "Bohai Gene has a research project, but it is not a research project to edit the baby gene."
According to the reporter's access to public information, the rumor came from the public announcement of the Shenzhen Technology Development Project 2015 (Fourth Lot) issued by the Shenzhen Science and Technology Innovation Committee on September 6, 2015. This list shows that the name of the project of Shenzhen Bohai Gene Biotechnology Co., Ltd. is single molecule sequencing technology and research and development, with a funding amount of 1.5 million yuan.
Gene Bohai Office